Back to top
more

Phibro Animal Health (PAHC)

(Delayed Data from NSDQ)

$26.49 USD

26.49
164,713

-0.10 (-0.38%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $26.48 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Phibro Animal Health (PAHC) Q4 Earnings Lag Estimates

by Zacks Equity Research

Phibro (PAHC) delivered earnings and revenue surprises of -10% and 0.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -300% and 5.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Investors Should Retain Phibro (PAHC) For Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) major animal health products and robust vaccine sales.

Zacks Equity Research

Phibro (PAHC) Up 7.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Phibro (PAHC) Business Hurt by Macro Issues, FX Fluctuations

by Zacks Equity Research

The increase in raw material costs and freight costs continues to pose challenges for Phibro (PAHC).

Zacks Equity Research

Phibro (PAHC) Q3 Earnings Lag Estimates, 2022 Revenue View Up

by Zacks Equity Research

In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.

Zacks Equity Research

Phibro Animal Health (PAHC) Q3 Earnings Miss Estimates

by Zacks Equity Research

Phibro (PAHC) delivered earnings and revenue surprises of -8.33% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Phibro (PAHC) Stock For Now

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC) owing to the robust performances by its Animal Health and Mineral Health segments.

Zacks Equity Research

The Zacks Analyst Blog Highlights Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group

by Zacks Equity Research

Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group are part of top Analyst Blog.

Riya Anand headshot

Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022

by Riya Anand

Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.

Zacks Equity Research

Is Phibro Animal Health (PAHC) a Good Stock for Value Investors?

by Zacks Equity Research

Let's see if Phibro Animal Health Corporation (PAHC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Zacks Equity Research

Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.

Zacks Equity Research

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Add Phibro (PAHC) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and diverse product lines.

Zacks Equity Research

Why Is Phibro (PAHC) Up 2.2% Since Last Earnings Report?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should Value Investors Buy These Medical Stocks?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Phibro Animal Health (PAHC) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Innoviva (INVA) and Phibro Animal Health (PAHC) have performed compared to their sector so far this year.

Zacks Equity Research

Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?

by Zacks Equity Research

Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.

Zacks Equity Research

Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing

by Zacks Equity Research

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.

Sanghamitra Saha headshot

Land on 5 Winning Stocks With the Overlooked Rising P/E Trick

by Sanghamitra Saha

Stocks with rising P/E often proves to be an intriguing investing idea.

Zacks Equity Research

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up

by Zacks Equity Research

Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.

Zacks Equity Research

Here's Why You Should Retain Phibro (PAHC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.

Zacks Equity Research

Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth

by Zacks Equity Research

Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.